Fidelity Investments’ John Carlson and DoubleLine Capital LP’s Luz Padilla pursue different strategies in their emerging-market debt funds. One thing they have in common is buying bonds denominated in U.S. dollars.
Takeover speculation, shareholder activism and regulatory scrutiny that erased about $2 billion from its share value are making options in Ariad Pharmaceuticals Inc. among the most expensive in America.
Pacific Investment Management Co.’s Scott Mather, one of its six new deputy chief investment officers, said the firm bought Mexican and Brazilian government debt in the past month amid a selloff in emerging-market assets.
Pacific Investment Management Co., the world’s biggest bond manager, named four deputy chief investment officers in an overhaul of its leadership team after Mohamed El-Erian’s decision last week to step down as chief executive officer.
Pacific Investment Management Co., the world’s biggest bond manager, plans to start 19 actively managed exchange-traded funds as co-founder Bill Gross further diversifies the firm following Chief Executive Officer Mohamed El-Erian’s resignation last week.
Ariad Pharmaceuticals Inc., the cancer-therapy developer that lost 64 percent of its market value last year, rose for a third day as investors bet the company may attract interest from larger drugmakers.